公开(公告)号：US20220017530A1

公开(公告)日：2022-01-20

申请号：US17475733

申请日：2021-09-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61P1/10 ,  A61K31/4355

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10548877B2

公开(公告)日：2020-02-04

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Kouji Fuji ,  Tomohiro Ohashi ,  Makoto Fushimi ,  Kei Masuda ,  Tatsuki Koike ,  Takeshi Wakabayashi ,  Jinichi Yonemori ,  Masami Yamada

IPC: A61K31/4192 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61P25/20 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  C07D213/56 ,  C07D231/12 ,  C07D249/06 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

公开(公告)号：US10106556B2

公开(公告)日：2018-10-23

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Tatsuki Koike ,  Jumpei Aida ,  Makoto Fushimi ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Masako Miyazaki ,  Hidekazu Tokuhara ,  Yasushi Hattori ,  Makoto Kamata

IPC: C07D498/04 ,  C07D413/14 ,  C07D401/06 ,  C07D413/06 ,  C07D417/14 ,  C07D471/04 ,  C07D401/10 ,  C07D413/10 ,  C12N9/99 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09624170B2

公开(公告)日：2017-04-18

申请号：US15108000

申请日：2014-12-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Makoto Fushimi ,  Jumpei Aida ,  Shuhei Ikeda ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Hidekazu Tokuhara

IPC: C07D207/273 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D471/04 ,  C07D405/12 ,  C07D417/14 ,  C07D417/12 ,  C07D413/12 ,  C07D403/04 ,  C07D401/14

CPC classification number: C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11236099B2

公开(公告)日：2022-02-01

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10202376B2

公开(公告)日：2019-02-12

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Yuhei Miyanohana ,  Masaki Ogino ,  Yuta Tanaka ,  Makoto Fushimi ,  Tomohiro Okawa ,  Yuki Hanya ,  Tatsuki Koike

IPC: C07D471/04 ,  A61K31/437 ,  C07D487/04 ,  A61P25/00 ,  A61P29/00

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

公开(公告)号：US09550756B2

公开(公告)日：2017-01-24

申请号：US14517313

申请日：2014-10-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko Taniguchi ,  Jun Kunitomo ,  Masato Yoshikawa ,  Makoto Fushimi

IPC: A61K31/501 ,  C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  A61K9/20

CPC classification number: C07D403/04 ,  A61K9/2059 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on.A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症等的药物。 式（I 0）的化合物：其中R 1表示取代基，R 2表示氢原子或取代基，R 3表示氢原子或取代基，环A表示可被取代的芳香环， 环B表示可被取代的5元杂芳环或其盐。